MetaCap

Mustang Bio Inc. (MBIO)

NASDAQ: MBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.3541-0.0159 (-4.30%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MBIO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.51
52-week range
0.35 – 1.43
Day range
0.3541 – 0.379
Volume / Avg
84.29K / 33.87K
Beta
—

52-week range

$0.35$1.43

MBIO stock today

On Nov 20, MBIO ended the session at $0.3541, shedding $0.0159 (4.30%), versus the S&P 500's 3.70% decline. Volume was 2.5x the average at 84.29K shares, a sign of unusually heavy trading. Shares are 75.2% below their 52-week high of $1.43 and 1.2% above the 52-week low of $0.35, near the bottom of the past year's range.

Mustang Bio has posted a net loss over the last twelve months (EPS of -$0.51), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Mustang Bio

Company profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Manuel Litchman M.D.
Headquarters
Waltham, MA
Employees
4

Financial highlights

Full financials

Mustang Bio reported a net loss of $1.9 million, compared with a loss of $15.8 million a year earlier. Diluted earnings per share came in at -$0.39.

Mustang Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-1.92M$-15.75M$-51.60M$-77.53M$-66.37M
EPS (diluted)$-0.39$-38.57$-299.95$-10.09$-0.76

Earnings

Earnings history
Last reported (Sep/2026)
Nov 6, 2026
EPS actual vs est.
$-0.14 vs —

Mustang Bio peers

Health Care sector
MBIO peer companies
CompanyPrice% ChgMarket capCompare
TRAWTraws Pharma Inc.0.175-23.91%$2.69Mvs MBIO
DRMADermata Therapeutics Inc.0.5095-4.23%$2.51Mvs MBIO
RDHLRedhill Biopharma Ltd. ADR0.281-13.08%$2.50Mvs MBIO
GRIGRI Bio Inc.1.120.00%$2.45Mvs MBIO
APUSApimeds Pharmaceuticals US Inc.1.60-8.05%$2.96Mvs MBIO
ONCOOnconetix Inc.2.89-8.54%$2.37Mvs MBIO
HCWBHCW Biologics Inc.0.7491+1.90%$2.35Mvs MBIO
JAGXJaguar Health Inc.0.227-30.58%$3.03Mvs MBIO

Indexes, lists and sector

Mustang Bio stock FAQ

What is Mustang Bio's stock price today?

MBIO last traded at $0.3541 as of Nov 20, 4:00 PM EST, down 4.30% on the day. Prices are delayed at least 15 minutes.

Who is Mustang Bio's CEO?

Dr. Manuel Litchman M.D. is the chief executive officer of Mustang Bio Inc., which has about 4 employees.

What is the MBIO 52-week high?

The 52-week high for MBIO is $1.43 and the 52-week low is $0.35. The stock is currently 75.2% below its high.

Compare MBIO